New Hire: MCIF is excited to welcome Kirsten Martin, PhD! Kirsten joined MCIF from Lawrence Berkeley National Labs where she was a Senior Scientific Engineering associate in the group of Dr. Rebecca Abergel. Kirsten received her Ph.D. from Stony Brook University performing radiometal-chelator research in Eszter Boros' group.
October 2024
New Hire: MCIF is proud to welcome Michael Montano, B.S. to the group! Michael comes to MCIF from Dana-Farber's radiation safety office, bringing a depth of knowledge in radioactive material handling and safety.
New Hire: MCIF is proud to welcome Dr. Erik Jimmy Jakobsson, PhD! Jimmy recently completed post-doctoral research at both the National Institutes of Health and subsequently at Washington University, Mallinckrodt Institute of Radiology in St. Louis, Missouri.
January 2023
New Hire: MCIF welcomes Lead Technician Anamae Azzopardi, MSc, to the team! Anamae bring previous experience in radiopharmaceutical GMP manufacturing and quality control.
August 2022
New Hire: MCIF is proud to welcome Dr. Hyunjung Kim to the team! Dr. Kim recently completed her post-doctoral studies at University of California San Francisco in the lab of Dr. Michael Evans, and Samsung Medical Center in the lab of Dr. Yearn Seong Choe.
New Hire: MCIF is excited to welcome Dr. Shin Hye (Grace) Ahn to the team! Dr. Ahn recently completed her post-doctoral studies at Stony Brook University in the lab of Dr. Eszter Boros.
January 2020
Research Grant Awarded: SNMMI 2020 Mitzi & William Blahd, MD, Pilot Research Grant "Development of a PET radiotracer for imaging KRAS G12C in NSCLS" Mark Dornan, Ph.D.
June 2020
Promotion: Anthony Belanger, Ph.D. promoted to Scientific Director, Lead Scientist in MCIF
October 2019
Research Grant Awarded: DFCI Friends of DFCI 2020 Award "The first in vivo-evaluation of BRAF PET imaging" Mark Dornan, Ph.D.
Publications & Presentations:
June 2025
Presentation: “Pre-clinical development of next-generation FAP-targeting radioligands with improved tumor retention” To be presented by Kyle Novakowski at the 2025 SNMMI annual meeting, New Orleans, LA (June 2025).
Presentation: “Preclinical characterization of 177Lu- and 225Ac-PNT6555 in multiple syngeneic murine tumor models,” Takashima, M; Kwon, O.; Vito, A.; Hallett, R.; Rodriguez, D.; Ahn, S. H.; Belanger, A.; Kumari, R.; Clark, P. A.; Chen, T.; Bednarz, B.; Morris, Z. Presented by Alyssa Vito at the American Radium Society Meeting 2024, Palm Spring, CA (May 2024).
Presentation: “Preclinical application of novel isotopes and combination therapy with the FAP-targeted ligand PNT6555,” Novakowski, K. E; Ahn, S. H.; Dornan, M. H.; Belanger, A. P.; Poplawski, S. E.; Bachovchin, W. W.; Hallett, R. M. Presented by Kyle Novakowski at the Society of Nuclear Medicine and Molecular Imaging 2023 Annual Meeting, Chicago, Il (June 2023)
May 2023
Presentation: “Method development for centralized clinical production of 177Lu-PSMA-I&T,” Dornan, M. H.; Southcott, L.; Ahn, S. H.; Belanger, A. P.; Hergott, V. S.; McCann, J. A. B. Presented by Lily Southcott at the International Society of Radiopharmaceutical Sciences 2023 Biannual Meeting, Honolulu, HI (May 2023)
Presentation: “Development and characterization of a next-generation 225Ac-PSMA radioligand,” Vito A, Dornan M, Beale T, Felten A, Ernste M, Nguyen Q, Ahn S, Belanger AP, Pan S, Wu W, Liu Y, Lai JH, Bachovchin WW, Hergott V, McCann J, Hallett R. European Association of Nuclear Medicine 2022 Annual Meeting, Barcelona, Spain, (October 2022)
September 2022
Presentation: “18F-Fluciclovine Delineates PSMA-Suppressed Castration Resistant Prostate Cancer,” Bakht M, Yamada Y, Ku SY, Venkadakrishnan VB, Korsen J, Kalidindi TM, Mizuno K, Ahn SH, Seo JH, Garcia MM, Khani F, Elemento O, Long H, Freedman M, Chaglassian A, Belanger AP, Nguyen QD, Pillarsetty NVK, Lewis J, Beltran H. World Molecular Imaging Congress 2022 annual meeting, Miami, FL (September 2022)
